ArticleHaematologica2016
C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas.
Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.American journal of hematology · 2017Trial
- Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphoma.Frontiers in immunology · 2025Article
- Angioimmunoblastic T-cell lymphoma harboring a t(8;14)(q24;q11.2)/TCR::MYC translocation that presented with intestinal infiltration.Annals of hematology · 2025Article
- Cellular redox homeostasis maintained by malic enzyme 2 is essential for MYC-driven T cell lymphomagenesis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- PTCL, NOS: An update on classification, risk-stratification, and treatment.Frontiers in oncology · 2023Review
- Article
- A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.EMBO molecular medicine · 2022Article
- Review
- Targeting the DNA Damage Response to Increase Anthracycline-Based Chemotherapy Cytotoxicity in T-Cell Lymphoma.International journal of molecular sciences · 2022Article
- Association between c-Myc Expression with Clinicopathological Features in T And NK Cell Lymphomas.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers.Diagnostic pathology · 2021Article
- T-Cell Acute Lymphoblastic Leukemia-Current Concepts in Molecular Biology and Management.Biomedicines · 2021Review
- Molecular understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS): A complex disease category.Journal of clinical and experimental hematopathology : JCEH · 2021Review
- Indolent T-Cell Lymphoproliferative Disorders of the Gastrointestinal Tract (iTLPD-GI): A Review.Cancers · 2021Review
- Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract.Haematologica · 2020Article
- Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma.Scientific reports · 2020Article
- GATA-3 in T-cell lymphoproliferative disorders.IUBMB life · 2020Review
- The role of aurora A and polo-like kinases in high-risk lymphomas.Blood advances · 2019Review
- Article
- TCRP1 transcriptionally regulated by c-Myc confers cancer chemoresistance in tongue and lung cancer.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.